Opens in a new tab

2seventy bio v Johnson & Johnson (CFI, 23 September 2026)

Date23 September 2026
CourtCFI
DivisionBrussels (BE) Local Division
Type of actionInfringement Action
Case number(s)UPC_CFI_29/2026
Registry referenceUPC-CFI-0000029/2026
Parties2seventy bio, Inc. v. Johnson & Johnson, Janssen Biotech, Inc., Janssen Pharmaceuticals Inc., Janssen-Cilag International NV, Janssen Pharmace…
LanguageEnglish

Official decision (PDF) · UPC registry entry

Case timeline

Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.

Contact the firm

Dhenne Avocats · 19 October 2026

Our analysis

Summary

In this CAR-T life sciences infringement action, the Brussels Local Division dismissed the defendants’ Rule 190 RoP applications for production of evidence directed at documents of the NIH (laboratory notebooks, invention reports, grant files, notice records), rejected the NIH’s request to be reclassified from intervener to co-claimant in the infringement action, and reserved costs. The court held that a Rule 190 order requires, among cumulative conditions, that the underlying claims be plausible on the basis of reasonably available evidence, a threshold the defendants’ entitlement-based challenge to 2seventy bio’s standing did not meet at this stage.

Why it matters

The order, published with seven official headnotes, gives structured guidance on three recurring questions. First, on intervention: the Rules of Procedure do not allow interventions in which the intervener directs claims against other parties, and a counterclaim for revocation makes the intervening patent holder a defendant to that counterclaim without making it a co-claimant in the infringement action. Second, on Rule 8.4 RoP: the fiction that the registered proprietor is treated as proprietor applies, in the court’s words, “only for the application of the RoP and more specifically the administrative tasks to be performed by the Court”, so that entitlement may be raised as a substantive defence and the presumption is rebuttable. Third, on Article 47 UPCA: prior notice to the proprietor is assessed at the date the action is recorded in the register and the burden of proving compliance lies on the claimant. The practical consequence is that defendants cannot use Rule 190 as a discovery tool to build a speculative entitlement defence, while licensees suing under Article 47 must document prior notice before filing.

Practical point

Exclusive licensees preparing UPC actions should assemble contemporaneous proof of prior notice to the proprietor before lodging the Statement of claim, since later production requests aimed at the proprietor’s files will not cure a standing gap.

Summary prepared by Dhenne Avocats. Only the official text of the decision is authoritative.

Decisions in the same proceedings

Going further

Lexicon: Supplementary protection certificate (SPC), Biosimilar medicinal product, Launch at risk.

Dhenne Avocats blog: Pharmaceutical patents and the UPC: is the Court hostile to them?.

Publications by Matthieu Dhenne: The Launch Letter: How Generics and Biosimilars Should Write to Avoid UPC Urgency (Kluwer Patent Blog).

Source and translations

Official source
Unified Patent Court registry link recorded in the record
Original language
English from the language of proceedings
Translation available
no translation recorded the firm’s French record is a summary, not a translation
Date checked
not recorded
Only the official text is authoritative. A machine translation is never presented as official, republishing a third-party document requires a verified basis in rights, and a link to the source is preferred.

Follow this case

Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.

Proceedings

  • UPC_CFI_29/2026 official number

Follow this case

Parties

Exact name as it appears in the record, group affiliation only where sourced and dated.

Decisions in the same proceedings and documented appeals

  1. 15 June 2026 2seventy bio v Johnson & Johnson (CFI, UPC_CFI_29/2026, 15 June 2026) Infringement Action · UPC_CFI_29/2026

    Avec l'accord des parties, la division locale de Bruxelles instruit ensemble l'action en contrefaçon et les demandes reconventionnelles en nullité, et un juge technicien sera demandé.

  2. 23 September 2026 2seventy bio v Johnson & Johnson (CFI, 23 September 2026) Infringement Action · UPC_CFI_29/2026

What the record states

Nature of the act
Infringement Action
Outcome (Dhenne Avocats summary)
In this CAR-T life sciences infringement action, the Brussels Local Division dismissed the defendants' Rule 190 RoP applications for production of evidence directed at documents of the NIH (laboratory notebooks, invention reports, grant files, notice records), rejected the NIH's request to be reclassified from intervener to co-claimant in the infringement action, and reserved costs. The court held that a Rule 190 order requires, among cumulative conditions, that the underlying claims be plausible on the basis of reasonably available evidence, a threshold the defendants' entitlement-based challenge to 2seventy bio's standing did not meet at this stage.
Appeal
No appeal documented in the corpus, this does not mean that no appeal was lodged.
Instance
First-instance decision, whether it has become final is not recorded.

Related decisions cited in the analyses

Scope: Dhenne Avocats corpus. Registry-based links are marked “official number”; links derived from the analyses are marked as such. An erroneous link can be withdrawn without deleting any record.

Receive an alert

Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.

Follow

Weekly summary, on Fridays.